{"task_id": "d8c1060873af8caa", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 278/464)", "text": "\nCOCCIDIOIDOMYCOSIS (CONT\u2019D)\nFungal Infections\n267\n\n--- Page 289 ---\nAntifungal Agents\nMechanism\nCandida Cryptococcus Aspergillus Other\nmoldsa\nDimorphicb Zygomycotac Renal\nadjustments\nAzoles\nFluconazoled\n100\u2013400 mg\nPO/IV daily\nInhibits CP450\n(convert\nlanosterol\n++C. alb +++\n+\nYes (dose)\nItraconazolee\n100\u2013200 mg\nPO daily\u2013BID\nto ergosterol on\ncell membrane)\n+++\n++\n++\n++\nNo\nVoriconazolef\n4 mg/kg IV\nq12h or\n200 mg PO BID\n+++\n+++\n++Fusa/\nScedo\n++\nNo but avoid IV\nform\nPosaconazole\n200 mg PO QID\n+++\n+++\n+++\n+++Fusa\n++\n+++\nNo\nAmphotericin Bg\nAmphotericin B\n0.3\u20131 mg/kg IV\nq24h\nBinds to ergosterol\non cell wall,\ncausing cell\nleakage\n+++\n+++\n++\n+\n+++\n+++\nYes (interval)\nLiposomal\nAmphoB\n3\u20135 mg/kg IV\nq24h\n+++\n+++\n++\n+\n+++\n+++\nYes (interval)\nAmphoB colloidal\ndispersion\n+++\n+++\n++\n+\n+++\n+++\nYes (interval)\nAmphoB lipid\ncomplex 5 mg/\nkg IV q24h\n+++\n+++\n++\n+\n+++\n+++\nYes (interval)\nEchinocandinh\nCaspofungin\n70 mg then\n50 mg IV q24h\nInhibits synthesis of\nb-1,3-d-glucan\non cell wall\n+++\n+++\n+Scedo\n+/\u2013\nNo\nMicafungin\n150 mg IV\nq24h\n+++\n+++\nNo\nAnidulafungin\n200 mg then\n100 mg IV\nq24h\n+++\n+++\nNo\n5-Flucytosine\nInhibits synthesis\nof DNA\n(thymidylate\nsynthetase)\n5 Flucytosine\n+++\n+++\n++\nYes (dose)\na other than Aspergillus, Fusarium, Scedosporium, and Pseudallescheria boydii are all examples of molds\nb dimorphic fungi include Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Paracoccidioides brasiliensis, and\nSporothrix schenckii\nc zygomycota fungi include Rhizopus, Mucor, and Absidia\nd fluconazole is ineffective against some Candida, Molds, and Zygomycetes\ne itraconazole is ineffective against some Candida, Scedosporium, and Zygomycetes. It has activity against Cryptococcus, but has less CSF\npenetration than fluconazole\nf voriconazole is ineffective against some Candida, Scedosporium, and Zygomycetes. It has activity against Cryptococcus, but has less CSF\npenetration than fluconazole\ng amphotericin B is ineffective against molds (Fusarium, Scedosporium, Trichosporum, Aspergillus terreus), C. guilliermondii and\nC. lusitaniae\nh caspofungin is ineffective against Zygomycetes, Cryptococcus, and Fusarium but probably has activity against other molds\nINDICATIONS FOR VORICONAZOLE\nINVASIVE ASPERGILLOSIS\nfirst line treatment for\ninvasive and CNS\nINVASIVE CANDIDIASIS\nsecond or third line treat\nment for patients who are refractory or intolerant of\nfluconazole (first line for some) or amphotericin B\n(first line for others)\nINDICATIONS FOR VORICONAZOLE (CONT\u2019D)\nFUNGEMIA\nempiric treatment for fungi not yet\nspeciated where neither amphotericin B nor flucona\nzole can be used\nFEBRILE NEUTROPENIA\nempiric antifungal treat\nment for patients intolerant of amphotericin B\n268\nAntifungal Agents", "text_length": 2712, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 278/464)", "type": "chunk", "chunk_index": 277, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.628329", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.629152", "status": "complete", "chunks_added": 2}